Healthcare / Medical DevicesNYSE
$4.58
-0.02 (-0.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-44.4M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-39.3%
↓Gross Margin
46.9%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+23.4%
FCF CAGR
—
FCF margin
-16.4%
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $97.6M · net income $-77.1M · FCF $-16.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $97.6M | $97.6M | $82.1M | $65.9M | $73.4M | $62.6M | $46.3M | $27.6M |
| Net Income | $-77.1M | $-77.1M | $-72.5M | $-133.7M | $-168.7M | $-32.4M | $-162.7M | $-99.7M |
| EBITDA | $-67.4M | $-67.4M | $-60.9M | $-123.0M | $-162.7M | $-190.6M | $-160.3M | $-101.5M |
| EPS | -0.31 | -0.31 | -0.34 | -0.65 | -0.84 | -0.19 | -26.87 | -17.08 |
| Gross Margin | 46.9% | 46.9% | 59.5% | 25.6% | 53.8% | 27.3% | -132.4% | -75.8% |
| Operating Margin | -88.5% | -88.5% | -90.7% | -221.0% | -263.0% | -308.0% | -349.4% | -370.9% |
| Net Margin | -79.0% | -79.0% | -88.3% | -202.9% | -229.9% | -51.8% | -351.9% | -361.4% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.10 | 0.10 | 0.14 | 0.11 | 0.10 | — | — | — |
| Current Ratio | 4.03 | 4.03 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-16.0M | $-16.0M | $-44.4M | $-104.6M | $-187.4M | $-197.1M | $-84.1M | $-124.9M |
| Returns | ||||||||
| ROE | -39.3% | -39.3% | -42.9% | -60.8% | -51.9% | -7.2% | 45.0% | 47.0% |
| Valuation | ||||||||
| P/B | 5.78 | 5.78 | 5.09 | 0.94 | 1.37 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 19.0% | 19.0% | 24.5% | -10.2% | — | 35.3% | 67.7% | — |
| EPS Growth | 8.8% | 8.8% | 47.7% | 22.6% | — | 99.3% | -57.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+98.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.34 → -0.31
Residual
+98.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.